共 11 条
- [1] Matrix contraction by dermal fibroblasts requires syndecan 4: Insights into pathological scarring in chronic fibrotic disease FASEB JOURNAL, 2006, 20 (05): : A1098 - A1098
- [5] Transforming Growth Factor (TGF)-β Type I Receptor Kinase (ALK5) Inhibitor Alleviates Profibrotic TGF-β1 Responses in Fibroblasts Derived from Peyronie's Plaque JOURNAL OF SEXUAL MEDICINE, 2010, 7 (10): : 3385 - 3395
- [6] Matrix contraction by dermal fibroblasts requires transforming growth factor-β/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK -: Insights into pathological scarring in chronic fibrotic disease AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (06): : 1699 - 1711
- [8] Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: Regulation by TGF-beta BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1996, 1312 (03): : 243 - 248
- [9] SKI2162, A NOVEL TRANSFORMING GROWTH FACTOR (TGF)-BETA TYPE I RECEPTOR KINASE (ALK5) INHIBITOR, ALLEVIATES PROFIBROTIC TGF-BETA1 RESPONSES IN FIBROBLASTS DERIVED FROM PEYRONIE'S PLAQUE JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 155 - 155